Fennec Pharmaceuticals Q2 2024 Earnings Report C$8.67 +0.16 (+1.88%) (As of 12/17/2024 ET) Earnings HistoryForecast Fennec Pharmaceuticals EPS ResultsActual EPS-C$0.27Consensus EPS C$0.08Beat/MissMissed by -C$0.35One Year Ago EPSN/AFennec Pharmaceuticals Revenue ResultsActual Revenue$9.94 millionExpected Revenue$18.67 millionBeat/MissMissed by -$8.73 millionYoY Revenue GrowthN/AFennec Pharmaceuticals Announcement DetailsQuarterQ2 2024Date8/13/2024TimeN/AConference Call ResourcesFRX Earnings History Trump’s Secret Manhattan Project (Ad)On January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just spent six months investigating this...and what I found is shocking.Click here and I’ll show you exactly how to position your money Fennec Pharmaceuticals Earnings HeadlinesFennec Pharmaceuticals (TSE:FRX) Shares Down 0.3% - Here's What HappenedDecember 13, 2024 | americanbankingnews.comFennec Pharmaceuticals (FENC) Gets a Buy from Craig-HallumNovember 7, 2024 | markets.businessinsider.comTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just spent six months investigating this...and what I found is shocking.December 18, 2024 | Banyan Hill Publishing (Ad)Fennec announces three executive appointmentsOctober 29, 2024 | markets.businessinsider.comFennec Pharmaceuticals Inc.September 5, 2024 | wsj.comFennec Pharmaceuticals Inc (FRX)August 16, 2024 | investing.comSee More Fennec Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Fennec Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Fennec Pharmaceuticals and other key companies, straight to your email. Email Address About Fennec PharmaceuticalsFennec Pharmaceuticals (TSE:FRX) operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.View Fennec Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Cintas (12/19/2024) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
